Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 2
2004 1
2005 1
2006 2
2007 3
2009 5
2010 4
2012 2
2014 2
2015 1
2017 1
2018 1
2020 4
2021 3
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

32 results
Results by year
Filters applied: . Clear all
Page 1
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.
Poon E, Liang T, Jamin Y, Walz S, Kwok C, Hakkert A, Barker K, Urban Z, Thway K, Zeid R, Hallsworth A, Box G, Ebus ME, Licciardello MP, Sbirkov Y, Lazaro G, Calton E, Costa BM, Valenti M, De Haven Brandon A, Webber H, Tardif N, Almeida GS, Christova R, Boysen G, Richards MW, Barone G, Ford A, Bayliss R, Clarke PA, De Bono J, Gray NS, Blagg J, Robinson SP, Eccles SA, Zheleva D, Bradner JE, Molenaar J, Vivanco I, Eilers M, Workman P, Lin CY, Chesler L. Poon E, et al. Among authors: vivanco i. J Clin Invest. 2020 Nov 2;130(11):5875-5892. doi: 10.1172/JCI134132. J Clin Invest. 2020. PMID: 33016930 Free PMC article.
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK. Lee JC, et al. Among authors: vivanco i. PLoS Med. 2006 Dec;3(12):e485. doi: 10.1371/journal.pmed.0030485. PLoS Med. 2006. PMID: 17177598 Free PMC article.
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
Smyth EC, Vlachogiannis G, Hedayat S, Harbery A, Hulkki-Wilson S, Salati M, Kouvelakis K, Fernandez-Mateos J, Cresswell GD, Fontana E, Seidlitz T, Peckitt C, Hahne JC, Lampis A, Begum R, Watkins D, Rao S, Starling N, Waddell T, Okines A, Crosby T, Mansoor W, Wadsley J, Middleton G, Fassan M, Wotherspoon A, Braconi C, Chau I, Vivanco I, Sottoriva A, Stange DE, Cunningham D, Valeri N. Smyth EC, et al. Among authors: vivanco i. Gut. 2021 Sep;70(9):1632-1641. doi: 10.1136/gutjnl-2020-322658. Epub 2020 Nov 16. Gut. 2021. PMID: 33199443 Free PMC article. Clinical Trial.
Inhibitors in AKTion: ATP-competitive vs allosteric.
Lazaro G, Kostaras E, Vivanco I. Lazaro G, et al. Among authors: vivanco i. Biochem Soc Trans. 2020 Jun 30;48(3):933-943. doi: 10.1042/BST20190777. Biochem Soc Trans. 2020. PMID: 32453400 Free PMC article. Review.
Targeting molecular addictions in cancer.
Vivanco I. Vivanco I. Br J Cancer. 2014 Nov 25;111(11):2033-8. doi: 10.1038/bjc.2014.461. Epub 2014 Sep 30. Br J Cancer. 2014. PMID: 25268375 Free PMC article. Review.
Targeting un-MET needs in advanced non-small cell lung cancer.
Coleman N, Harbery A, Heuss S, Vivanco I, Popat S. Coleman N, et al. Among authors: vivanco i. Lung Cancer. 2022 Feb;164:56-68. doi: 10.1016/j.lungcan.2021.12.016. Epub 2021 Dec 29. Lung Cancer. 2022. PMID: 35033939 Review.
A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity.
Kostaras E, Kaserer T, Lazaro G, Heuss SF, Hussain A, Casado P, Hayes A, Yandim C, Palaskas N, Yu Y, Schwartz B, Raynaud F, Chung YL, Cutillas PR, Vivanco I. Kostaras E, et al. Among authors: vivanco i. Br J Cancer. 2020 Aug;123(4):542-555. doi: 10.1038/s41416-020-0889-4. Epub 2020 May 22. Br J Cancer. 2020. PMID: 32439931 Free PMC article.
32 results